Dear Editor

On March 2020, the World Health Organization declared current outbreak of the 2019 coronavirus disease (COVID-19), caused by SARS-CoV-2, a global pandemic.

Since its recent identification, little is known about managing infected patients, especially if they have coexisting rare diseases in need of treatment. Here, we report the first case of severe recurrence of secondary immune thrombocytopenia (ITP), triggered by COVID-19.

On 4th April 2020, a 37-year-old female presented to the emergency department because of abrupt appearance of low extremities purpura. She reported suffering from chronic ITP secondary to systemic lupus erythematosus. The latter was diagnosed in 2003 and treated with mycophenolate-mofetil since 2013. Severe ITP recurrences after deliveries (2010 and 2013) and during a viral rhino-sinusitis (2016) had required hospitalisation and intra-venous immune globulins (IVIG) administration.

Two weeks before current admission, the patient had a self-resolved episode of fever (37.5 °C) accompanied by fatigue, dry cough and anosmia. Anyway, standard chest X-ray did not evidence lung infiltrates.

Complete blood cell count (CBC) showed isolated severe thrombocytopenia (6000/mmc), while C-reactive protein, lymphocyte count, D-dimers, anti-phospholipid/cardiolipin autoantibodies and lupus-anticoagulant were within normal ranges.

A familial cluster for SARS-CoV-2 was reported: patient's father had been admitted for moderate COVID-19 pneumonia 1 week before. Their last contact occurred 19 days earlier.

Therefore, we decided to perform the rhino-pharyngeal swab for SARS-CoV-2 that resulted positive.

During hospitalisation, mycophenolate-mofetil was discontinued, and IVIG and intra-venous methyl-prednisolone were administered. The patient received also a 7-day combination of hydroxichloroquine and lopinavir/ritonavir. SARS-CoV-2 swabs performed at day 6 and 8 demonstrated negative results. Daily, platelet count gradually increased up to 77,000/mmc at time of discharge (day 11). Low-molecular weight heparin prophylaxis was not instituted due to bleeding concern; however, the careful monitoring of D-dimers levels always revealed normal values. One week later, the CBC done in the outpatient clinic showed a platelet count of 119,000/mmc (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Timeline of platelet count after treatment of secondary (systemic lupus erythematosus-related) ITP recurrence in a 37-year-old female patient with COVID-19 infection. IVIG, intra-venous immune globulins; IVMP, intra-venous methyl-prednisolone; PDN, prednisone

This is the first case of secondary ITP in the context of COVID-19. Differently from a recent report of primary ITP presenting with symptomatic pneumonia \[[@CR1]\], our patient had only mild symptoms. Personal history of triggered ITP recurrences and the interval of time between intra-familial exposure and development of ITP relapse strongly argue in favour of SARS-CoV-2 causative role.

Newly diagnosed or recurrent ITP cases due to COVID-19 infection raise many therapeutic challenges. As recently reported, up to 20% of patients hospitalized for SARS-CoV-2 develop thromboembolic events \[[@CR2]\] \[[@CR3]\]. Therefore, in the event of ITP, a major concern could be the use of thrombopoietin-receptor agonists, owing to their limited but not negligible pro-thrombotic potential \[[@CR4]\].

Consistently with the British practical guidelines for ITP patients at time of COVID-19 infection \[[@CR5]\], we adopted a more cautious therapeutic strategy that initially included IVIG, followed by corticosteroids. The latter are subject of debate for COVID-19 treatment, but they could be of benefit in case of ARDS \[[@CR6]\].

In conclusion, this case suggests that SARS-CoV-2 infection might trigger ITP. Management of these coexisting conditions is challenging and requires a careful balance between the risk of severe bleeding and of infection-related thromboembolic events.
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